Recently, Biological Industries (BI) submitted a Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for purposes of moving its NutriStem® hPSC XF Medium toward being certified for clinical applications. The product is a defined, xeno-free (XF), serum-free (SF) medium that supports the growth and expansion of human induced pluripotent stem (iPS) and embryonic stem cells (ESCs). [Read more…]
CariCord Partners with Singapore’s CellResearch Corp to Join “Global Cord Registry” & Launch Cord Tissue Storage in U.S.
Singapore’s CellResearch Corporation has entered into an agreement with CariCord to provide umbilical cord tissue banking services within the United States. CariCord is the private cord blood and tissue banking partner of ClinImmune Labs at the University of Colorado.
As stated in the November 30, 2016, press release:
“CellResearch Corporation Pte Ltd (“CellResearch”), a Singapore-based company that specializes in stem cell technology, through its wholly owned subsidiary, CordLabs Pte Ltd (“CordLabs”), has entered into an agreement with CariCord Inc. (“CariCord”) to provide umbilical cord tissue banking services in the United States. CariCord is the private postnatal cord blood and tissue banking partner of ClinImmune Labs (“ClinImmune”) at the University of Colorado, Anschutz Medical Campus (“UCAMC”).
This agreement extends CellResearch’s on-going collaboration with ClinImmune. The two groups are already working together to obtain US Federal Drug Agency (“US FDA”) approval for Corlicyte™, a drug for the treatment of diabetic wounds. ClinImmune will produce the world’s first Current Good Manufacturing Practices (“cGMP”) cord lining mesenchymal stem cell lines for therapeutic use.”
This license agreement also allows CariCord’s cord tissue clients to join CellResearch’s Global Cord Registry (“GCR”), “a proprietary registry for all clients who have saved cord lining stem cells with licensed partners.” The registry currently has 50,000+ registered clients, making it the largest group of its type in the world.
To learn more, read the full press release from CellResearch Corporation.
Allen Institute for Cell Science Releases Gene Edited Human Stem Cell Lines
First 5 cell lines in Allen Cell Collection empower the cell science community to explore the dynamic organization of the cell and to better understand health and disease
November 30, 2016 — The Allen Institute for Cell Science has released the Allen Cell Collection: the first publicly available collection of gene edited, fluorescently tagged human induced pluripotent stem cells that target key cellular structures with unprecedented clarity. Distributed through the Coriell Institute for Medical Research, these powerful tools are a crucial first step toward visualizing the dynamic organization of cells to better understand what makes human cells healthy and what goes wrong in disease.
“Each of our cells—the fundamental units of life—are like a city, with people and resources that move around and factories that generate those resources and carry out important functions,” says Rick Horwitz, Ph.D., Executive Director of the Allen Institute for Cell Science. “With these cell lines, we aim to give the cell science community a kind of live traffic map to see when and where the parts of the cell are with the clarity and consistency they need to make progress toward understanding human health and tackling disease. [Read more…]
Nohla Therapeutics Investors Provide $43.5M for Universal Donor Stem Cell Therapies
Seattle, Washington – Nohla Therapeutics Inc. (Nohla), a biotechnology company pioneering the field of universal donor cellular therapies for treating patients with life threatening hematological disorders and cancers, today announced the initial closing of a $43.5M Series A financing round. [Read more…]
Using HLA “Super Donors”, ORIG3N’s Crowdsourced Cell Repository Contains Donor Matches for 90% of U.S.
ORIG3N announced it has identified “super donor” matches for 90 percent of the U.S. population. The discovery will accelerate how quickly and successfully we match people for transplants, as tissue can be generated from these cells. ORIG3N was able to achieve this milestone approximately 5x faster than its Japanese counter parts because it has built the world’s largest crowdsourced cell repository called LifeCapsule.
HLA is short for “human leukocyte antigen.” It is a gene complex encoding the cell-surface proteins that control regulation of the human immune system. More simply, it is a protein found on most cells of your body that determines how your body recognizes what is you versus other.
HLA “super donors” are people with tissues that are immunologically compatible with a large percentage of the human population. They are very rare in the population, making them difficult to identify.
The signficanceof this announcement by ORIG3N is that for the first time in history, a complete set of matched samples has been identified and can be industrially produced. Utilizing induced pluripotent stem cell (iPSC) technology, any of the 200+ tissues that compose the human body can now be created.
Importantly, these tissues would be an exact match to the individuals requiring them, even though they were derived from another person (an allogenic transplant).
According to ORIG3N, in the near future, this approach may allow people to rapidly get an exact match for a transplant, instead of waiting for months. Instead, tissues could be “pre-produced.”
For more information, visit www.orig3n.com.
- « Previous Page
- 1
- …
- 117
- 118
- 119
- 120
- 121
- …
- 194
- Next Page »